Quarterly ResultAug 11, 2026, 08:17 AM
Mereo BioPharma Q2 Net Loss $7M; Alvelestat Deal with Sentynl
AI Summary
Mereo BioPharma Group plc announced its second quarter 2026 financial results, reporting a net loss of $7.0 million, a significant reduction from $14.6 million in the prior year. The company also entered into an option and license agreement with Sentynl Therapeutics for alvelestat, its investigational therapy for AATD-LD, with potential payments of up to $40 million upon option exercise. Cash and cash equivalents stood at $30.1 million, extending the cash runway into late-2027, and regulatory discussions for setrusumab are ongoing.
Key Highlights
- Q2 2026 net loss was $7.0 million, down from $14.6 million in Q2 2025.
- Cash and cash equivalents totaled $30.1 million as of June 30, 2026.
- Cash runway extended into late-2027, excluding potential deal payments.
- Entered option and license agreement with Sentynl Therapeutics for alvelestat.
- Eligible to receive $40 million in upfront and R&D payments upon option exercise by Sentynl.
- R&D expenses decreased by $3.6 million to $1.8 million in Q2 2026.
- G&A expenses decreased by $0.3 million to $5.2 million in Q2 2026.
- Engaging with regulatory agencies for setrusumab in osteogenesis imperfecta.
Price Impact
More from MREO